Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine (DW1865)

European Journal of Pharmacology

Volumn 702, Issue 1-3, 2013, Pages 218-226

  Oh, Kwang Seok ^a   Oh, Byung Koo ^a   Ho Park, Cheon ^a   Won Seo, Ho ^a   Sook Kang, Nam ^b   Hyun Lee, Jeong ^a   Soo Lee, Jin ^c   Ho Lee, Byung ^a,b  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Chungnam National University   (South Korea)

^c DongWha Pharm Ind Co   (South Korea)

Author keywords

Cardiovascular effect; Hypertension; Hypertrophy; Rho kinase

Indexed keywords

2 (1H INDAZOLE 5 YL)AMINO 4 METHOXY 6 PIPERAZINOTRIAZINE; ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II; DW 1865; F ACTIN; FASUDIL; MYOSIN LIGHT CHAIN 2; MYOSIN PHOSPHATASE 1; PHENYLEPHRINE; PHOSPHATASE; RHO KINASE; RHO KINASE 1; RHO KINASE 2; RHO KINASE INHIBITOR; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEART HYPERTROPHY; HEART RATE; HYPERTENSION; IC 50; IN VITRO STUDY; MALE; MEAN ARTERIAL PRESSURE; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STRESS FIBER; THORACIC AORTA; VASCULAR TISSUE; VASODILATATION;

ACTINS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; CARDIAC MYOSINS; CELL LINE; HYPERTENSION; INDAZOLES; MALE; MYOSIN LIGHT CHAINS; MYOSIN-LIGHT-CHAIN PHOSPHATASE; PROTEIN KINASE INHIBITORS; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; TRIAZINES; VASODILATION;

EID: 84874405559     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.01.027     Document Type: Article

References (35)

1. M. Amano, Y. Fukata, and K. Kaibuchi Regulation and functions of Rho-associated kinase Exp. Cell Res. 261 2000 44 51
2. A.A. Birukova, K. Smurova, K.G. Birukov, P. Usatyuk, F. Liu, K. Kaibuchi, A. Ricks-Cord, V. Natarajan, I. Alieva, J.G. Garcia, and A.D. Verin Microtubule disassembly induces cytoskeletal remodeling and lung vascular barrier dysfunction: role of Rho-dependent mechanisms J. Cell Physiol. 201 2004 55 70
3. C. Breitenlechner, M. Gassel, H. Hidaka, V. Kinzel, R. Huber, R.A. Engh, and D. Bossemeyer Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity Structure 11 2003 1595 1607
4. B.R. Brooks, C.L. Brooks 3rd, A.D. Mackerell Jr., L. Nilsson, R.J. Petrella, B. Roux, Y. Won, G. Archontis, C. Bartels, S. Boresch, A. Caflisch, L. Caves, Q. Cui, A.R. Dinner, M. Feig, S. Fischer, J. Gao, M. Hodoscek, W. Im, K. Kuczera, T. Lazaridis, J. Ma, V. Ovchinnikov, E. Paci, R.W. Pastor, C.B. Post, J.Z. Pu, M. Schaefer, B. Tidor, R.M. Venable, H.L. Woodcock, X. Wu, W. Yang, D.M. York, and M. Karplus CHARMM: the biomolecular simulation program J. Comput. Chem. 30 2009 1545 1614
5. C. Chaponnier, and G. Gabbiani Pathological situations characterized by altered actin isoform expression J. Pathol. 204 2004 386 395
6. J.D. Ginn, T. Bosanac, R. Chen, C. Cywin, E. Hickey, M. Kashem, S. Kerr, S. Kugler, X. Li, A. Prokopowicz 3rd, S. Schlyer, J.D. Smith, M.R. Turner, F. Wu, and E.R. Young Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: Part 2, optimization for blood pressure reduction in spontaneously hypertensive rats Bioorg. Med. Chem. Lett. 20 2010 5153 5156
7. C. Hahmann, and T. Schroeter Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity Cell. Mol. Life Sci. 67 2010 171 177
8. M. Hammond, D.G. Washburn, H.T. Hoang, S. Manns, J.S. Frazee, H. Nakamura, J.R. Patterson, W. Trizna, C. Wu, L.M. Azzarano, R. Nagilla, M. Nord, R. Trejo, M.S. Head, B. Zhao, A.M. Smallwood, K. Hightower, N.J. Laping, C.G. Schnackenberg, and S.K. Thompson Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors Bioorg. Med. Chem. Lett. 19 2009 4441 4445
9. E. Hu, and D. Lee Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases Curr. Opin. Invest. Drugs 4 2003 1065 1075
10. G.S. Hwang, K.S. Oh, H.N. Koo, H.W. Seo, K.H. You, and B.H. Lee Effects of KR-31378, a novel ATP-sensitive potassium channel activator, on hypertrophy of H9c2 cells and on cardiac dysfunction in rats with congestive heart failure Eur. J. Pharmacol. 540 2006 131 138
11. T. Ishizaki, M. Maekawa, K. Fujisawa, K. Okawa, A. Iwamatsu, A. Fujita, N. Watanabe, Y. Saito, A. Kakizuka, N. Morii, and S. Narumiya The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase EMBO J. 15 1996 1885 1893
12. K. Katoh, Y. Kano, M. Amano, K. Kaibuchi, and K. Fujiwara Stress fiber organization regulated by MLCK and Rho-kinase in cultured human fibroblasts Am. J. Physiol. Cell Physiol 280 2001 C1669 C1679
13. Y. Kawano, T. Yoshimura, and K. Kaibuchi Smooth muscle contraction by small GTPase Rho Nagoya J. Med. Sci. 65 2002 1 8
14. B.H. Lee, H.W. Seo, K.J. Kwon, S.E. Yoo, and H.S. Shin In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist J. Cardiovasc. Pharmacol. 33 1999 375 382
15. P.V. LoGrasso, and Y. Feng Rho kinase (ROCK) inhibitors and their application to inflammatory disorders Curr. Top Med. Chem. 9 2009 704 723
16. M. Malakhova, I. D'Angelo, H.G. Kim, I. Kurinov, A.M. Bode, and Z. Dong The crystal structure of the active form of the C-terminal kinase domain of mitogen- and stress-activated protein kinase 1 J. Mol. Biol. 399 2010 41 52
17. C. McInnes, M. Mezna, and G. Kontopidis Catch the kinase conformer Chem. Biol. 13 2006 693 694
18. K. Miyata, H. Hitomi, P. Guo, G.X. Zhang, S. Kimura, H. Kiyomoto, N. Hosomi, S. Kagami, M. Kohno, and A. Nishiyama Possible involvement of Rho-kinase in aldosterone-induced vascular smooth muscle cell remodeling Hypertens. Res. 31 2008 1407 1413
19. M. Moey, V. Rajapurohitam, A. Zeidan, and M. Karmazyn Ginseng (Panax quinquefolius) attenuates leptin-induced cardiac hypertrophy through inhibition of p115Rho guanine nucleotide exchange factor-RhoA/Rho-associated, coiled-coil containing protein kinase-dependent mitogen-activated protein kinase pathway activation J. Pharmacol. Exp. Ther. 339 2011 746 756
20. M. Montes, M.A. Miteva, and B.O. Villoutreix Structure-based virtual ligand screening with LigandFit: pose prediction and enrichment of compound collections Proteins 68 2007 712 725
21. B.K. Mueller, H. Mack, and N. Teusch Rho kinase, a promising drug target for neurological disorders Nat. Rev. Drug Discovery 4 2005 387 398
22. O. Nakagawa, K. Fujisawa, T. Ishizaki, Y. Saito, K. Nakao, and S. Narumiya ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice FEBS Lett. 392 1996 189 193
23. + (BKCa) channels are involved in the vascular relaxations elicited by piceatannol isolated from Rheum undulatum rhizome Planta Med. 73 2007 1441 1446
24. S. Pellegrin., and H. Mellor Actin stress fibres J. Cell Sci. 120 2007 3491 3499
25. K. Satoh, Y. Fukumoto, and H. Shimokawa Rho-kinase: important new therapeutic target in cardiovascular diseases Am. J. Physiol. Heart Circ. Physiol. 301 2011 H287 H296
26. H. Shimokawa, and A. Takeshita Rho-kinase is an important therapeutic target in cardiovascular medicine Arterioscler. Thromb. Vasc. Biol. 25 2005 1767 1775
27. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase Physiol. Rev. 83 2003 1325 1358
28. N. Takahashi, H. Tuiki, H. Saya, and K. Kaibuchi Localization of the gene coding for ROCK II/Rho kinase on human chromosome 2p24 Genomics 55 1999 235 237
29. M. Terrak, F. Kerff, K. Langsetmo, T. Tao, and R. Dominguez Structural basis of protein phosphatase 1 regulation Nature 429 2004 780 784
30. G. Totsukawa, Y. Yamakita, S. Yamashiro, D.J. Hartshorne, Y. Sasaki, and F. Matsumura Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts J. Cell Biol. 150 2000 797 806
31. M.J. van Eis, J.P. Evenou, P. Floersheim, C. Gaul, S.W. Cowan-Jacob, L. Monovich, G. Rummel, W. Schuler, W. Stark, A. Strauss, A. von Matt, E. Vangrevelinghe, J. Wagner, and N. Soldermann 2,6-naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes Bioorg. Med. Chem. Lett. 21 2011 7367 7372
32. A. Wirth Rho kinase and hypertension Biochim. Biophys. Acta 1802 2010 1276 1284
33. H. Yamaguchi, Y. Miwa, M. Kasa, K. Kitano, M. Amano, K. Kaibuchi, and T. Hakoshima Structural basis for induced-fit binding of Rho-kinase to the inhibitor Y-27632 J. Biochem. 140 2006 305 311
34. L. Yao, M.J. Romero, H.A. Toque, G. Yang, R.B. Caldwell, and R.W. Caldwell The role of RhoA/Rho kinase pathway in endothelial dysfunction J. Cardiovasc. Dis. Res. 1 2010 165 170
35. A. Zeidan, S. Javadov, and M. Karmazyn Essential role of Rho/ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes Cardiovasc. Res. 72 2006 101 111